US Patent Issued to City of Hope, The Board of Trustees of the Leland Stanford Junior University on Sept. 23 for "Targeted chimeric antigen receptor modified T cells for treatment of IL13RAlpha2 positive malignancies" (California Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,954, issued on Sept. 23, was assigned to City of Hope (Duarte, Calif.) and The Board of Trustees of the Leland Stanford Junior University (Stanford, Calif.).

"Targeted chimeric antigen receptor modified T cells for treatment of IL13RAlpha2 positive malignancies" was invented by Christine E. Brown (Duarte, Calif.), Lawrence Stern (Duarte, Calif.), Xin Yang (Duarte, Calif.), K. Christopher Garcia (Duarte, Calif.) and Ignacio Moraga Gonzalez (Duarte, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13RAlpha2 than IL13RAlpha1 by virtue of w...